共 69 条
[1]
Khan O(2015)Multiple sclerosis in US minority populations: clinical practice insights Neurol Clin Pract 5 132-142
[2]
Williams MJ(2012)Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N Engl J Med 367 1087-1097
[3]
Amezcua L(2017)Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study Mult Scler 23 253-265
[4]
Javed A(2012)Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N Engl J Med 367 1098-1107
[5]
Larsen KE(2017)Efficacy and tolerability of delayed-release dimethyl fumarate in black, Hispanic, and Asian patients with relapsing-remitting multiple sclerosis: post hoc integrated analysis of DEFINE and CONFIRM Neurol Ther 6 175-187
[6]
Smrtka JM(2016)Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis Ther Adv Neurol Disord 9 454-461
[7]
Fox RJ(2003)Multiple sclerosis in children Brain Dev 25 229-232
[8]
Miller DH(2020)Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate J Neurol 267 125-131
[9]
Phillips JT(2004)Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis Neurology 63 2039-2045
[10]
Gold R(2010)Rapid disease course in African Americans with multiple sclerosis Neurology 75 217-223